Although our study demonstrates that Mst2 is a novel regulator of inflammation-related cardiomyocyte viability, further investigations are necessary to determine the therapeutic potential of targeting Mst2 in cardiovascular diseases. Here, STK3 is linked to cardiovascular disorder.